We examined the value of targeted molecular screening for the identification of uterine anaplastic lymphoma kinase (ALK)-rearranged mesenchymal tumors, including ALK immunohistochemistry followed by molecular genetic testing, in all uterine leiomyosarcomas and STUMPs (smooth muscle tumors of uncertain malignant potential). All leiomyosarcoma and STUMP cases diagnosed in a 10-year period (2006-2016) at Charles University Faculty of Medicine in Pilsen were retrieved and reviewed. Of 23 cases, one case (LMS [leiomyosarcoma]) was positive for ALK rearrangement, namely, PPP1CB-ALK fusion gene. No specific histologic features (i.e., lymphocytic infiltrate and stromal edema) were observed in this case. This suggests that inflammatory myofibroblastic tumor (IMT)-like histologic features may not be an initial reliable screening tool in identifying uterine IMT cases. Thus, we proposed a two-step IHC and molecular genetic testing (as a reflex test) for IMT in all uterine LMS and STUMP cases. This will enhance the proper detection of such tumors at the population level and ultimately offer patients available targeted therapies.

• Klíčová slova
• ALK, IMT, Leiomyosarcoma, Molecular genetics, STUMP,
• MeSH
• anaplastická lymfomová kináza MeSH
• genetické testování metody   MeSH
• genová přestavba * MeSH
• imunohistochemie MeSH
• leiomyosarkom diagnóza   genetika   metabolismus   MeSH
• lidé MeSH
• nádor z hladké svalové tkáně diagnóza   genetika   metabolismus   MeSH
• nádorové biomarkery genetika   metabolismus   MeSH
• nádory dělohy diagnóza   genetika   metabolismus   MeSH
• retrospektivní studie MeSH
• tyrosinkinasové receptory genetika   metabolismus   MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• ALK protein, human MeSH Prohlížeč
• anaplastická lymfomová kináza MeSH
• nádorové biomarkery MeSH
• tyrosinkinasové receptory MeSH